Opthea Ltd (ASX: OPT) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Opthea Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $738.77 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.23 billion
Earnings per share -0.282
Dividend per share N/A
Year To Date Return -25.93%
Earnings Yield N/A
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

  • Opthea Ltd (ASX: OPT)
    Latest News

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Lotus Resources, Opthea, Qoria, and Sims shares are charging higher today

    These shares are catching the eye on Thursday. But why?

    Read more »

    A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
    Share Gainers

    Why ARB, Guzman Y Gomez, Opthea, and Yancoal shares are storming higher

    These shares are starting the week with a bang. But why?

    Read more »

    Two lab workers fist pump each other.
    Healthcare Shares

    2 promising small-cap ASX healthcare stocks to buy now

    Theses two small-cap ASX healthcare shares could tap into the huge US medical market.

    Read more »

    surprised asx investor appearing incredulous at hearing asx share price
    Speculative

    'Blockbuster opportunity': This speculative ASX stock could rise 70%

    Bell Potter thinks exciting times could be around the corner for this buy-rated high risk stock.

    Read more »

    A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
    Share Gainers

    Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today

    These shares are starting the week with a bang. What's happening?

    Read more »

    a business man in a suit holds his hand over his eyes as he bows his head in a defeated post suggesting regret and remorse.
    Share Fallers

    Why Core Lithium, Deterra Royalties, Northern Star, and Opthea shares are dropping

    These shares are ending the week deep in the red. But why?

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling today

    These ASX shares are having a tough time on Thursday. But why?

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Opthea, Pantoro, Premier Investments, and Wildcat shares are falling

    These ASX shares are having a tough time on Tuesday. But why?

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why APA Group, Cettire, Deep Yellow, and Opthea shares are falling today

    These ASX shares are having a difficult session. Here's what's happening.

    Read more »

    A women cheers with clenched fists having read some good news on her laptop.
    Share Gainers

    Why Arcadium Lithium, Boart Longyear, Opthea, and Orecorp shares are rising today

    These ASX shares are having a positive start to the week. But why?

    Read more »

    A scientist examining test results.
    Healthcare Shares

    Why did the Opthea share price dive 9% on Monday?

    The biopharmaceutical company has announced new share issue arrangements.

    Read more »

    Close up of a sad young woman reading about declining share price on her phone.
    Share Fallers

    Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking

    These ASX shares are having a bad start to the week...

    Read more »

    Frequently Asked Questions

    OPT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Opthea Ltd

    Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage. 

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    17 Dec 2024 Lawrence Gozlan Expiry 2,000,000 $1,270,000
    Options expired.
    17 Dec 2024 Lawrence Gozlan Issued 2,000,000 $1,270,000
    Issue of options.
    17 Dec 2024 Jeremy Levin Issued 2,000,000 $1,270,000
    Issue of options.
    17 Dec 2024 Julia Haller Issued 1,000,000 $635,000
    Issue of options.
    17 Dec 2024 Susan Orr Issued 2,000,000 $1,270,000
    Issue of options. As per announcement on 17-12-2024
    17 Dec 2024 Quinton Oswald Issued 2,000,000 $1,270,000
    Issue of options. As per announcement on 17-12-2024
    17 Dec 2024 Anshul Thakral Issued 2,000,000 $1,270,000
    Issue of options.
    17 Dec 2024 Sujal Shah Issued 2,000,000 $1,270,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Lawrence Bernard Gozlan Non-Executive Director Jul 2020
    Mr. Gozlan, a biotechnology investor and advisor, is the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. Mr. Gozlan is also the Chief Investment Officer and Founder of Scientia Capital, a global investment fund focused exclusively on life sciences. Scientia was founded to provide expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the life sciences industry. Prior to this, Mr. Gozlan was responsible for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (the Queensland Investment Corporation), an investment fund with over $60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained senior corporate finance experience advising life science companies at Deloitte.
    Dr Jeremy Levin Non-Executive ChairmanNon-Executive Director Oct 2020
    Dr. Levin has served as the Chief Executive Officer of Ovid Therapeutics Inc. since 2015, and since 2014, as Chairperson of the board of directors, of Ovid. From May 2012 to October 2013, Dr. Levin served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. From September 2007 to December 2012, Dr. Levin held several roles at Bristol Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr. Levin also served as a member of the executive committee at Bristol Myers Squibb Company.
    Mr Sujal Arun Shah Non-Executive Director Apr 2024
    Mr. Shah is a biopharmaceutical executive with leadership and product development experience and a track record in capital formation that complements the expertise in retinal disease, especially wet AMD, of the Opthea Board. Most recently, Mr. Shah served as President and Chief Executive Officer of CymaBay Therapeutics which was acquired by Gilead Sciences for approximately $4.3 billion in total equity value in March 2024. Mr Sujal is chair of Risk Committee.
    Ms Katherine(Kathy) Ellen Danielle Connell Non-Executive Director Nov 2024
    Ms Connell is a commercial executive with business development expertise across pharmaceutical, vaccine, medtech, consumer and digital health industries. Her track record of translating global commercial strategies into impactful business results and shareholder value will be instrumental as Opthea prepares for the topline data readout of its pivotal program of sozinibercept in wet AMD. Ms. Connell is currently Senior Client Partner and Head of Healthcare and Life Sciences Australia/New Zealand at Korn Ferry. She also serves as Non-Executive Director at Avecho Biotechnology Ltd (ASX: AVE), Proto Axiom (a biotech investment company with an incubation arm) and BioNSW (life sciences association for NSW, Australia).
    Mrs Karen Adams Company SecretaryVice President of Finance Jun 2021
    -
    Dr Frederic Guerard Chief Executive Officer Oct 2023
    -
    Judith Robertson Chief Commercial Officer
    -
    Frederic Guerard Chief Executive Officer
    -
    Peter Lang Chief Financial Officer
    -
    Karen Adams Company SecretaryVice President of Finance
    -
    Fang Li Senior Vice President Regulatory Affairs
    -
    Julie Clark Senior Vice President of Clinical Development
    -
    Bruno Gagnon Senior Vice President Global Clinical Operations
    -
    Mark O'Neill Vice President CMC
    -
    John Han Vice President Medical Affairs
    -
    Kevin Bitter Vice President Strategy & Corporate Development
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 180,041,041 14.62%
    UBS Nominees Pty Ltd 164,238,358 13.34%
    HSBC Custody Nominees (Australia) Limited 151,845,051 12.33%
    JP Morgan Nominees Australia Pty Limited 151,418,346 12.30%
    BNP Paribas Noms Pty Ltd 64,844,903 5.27%
    HSBC Custody Nominees(Australia) Limited-Gsco Eda 60,000,000 4.87%
    National Nominees Limited 52,933,500 4.30%
    HSBC Custody Nominees (Australia) Limited-Gsi Eda 43,877,058 3.56%
    Merrill Lynch(Australia) Nominees Pty Limited 42,764,892 3.47%
    HSBC Custody Nominees (Australia) Limited A/C2 22,785,116 1.85%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 16,402,937 1.33%
    Jagen Pty Ltd 13,755,397 1.12%
    Est Ms Margaret Lynette Harvey 13,162,671 1.07%
    HSBC Custody Nominees(Australia) Limited <Nt Comnwlth Super Corp A/C> 12,420,253 1.01%
    Buttonwood Nominees Pty Ltd 11,311,250 0.92%
    Jadeglen Investments Pty Ltd <David Thurin Family A/C> i 9,004,711 0.73%
    Safo Investments Pty Ltd<Safo Investment A/C> 8,134,875 0.66%
    BNP Paribas Noms (Nz) Ltd 6,840,745 0.56%
    Armada Trading Pty Limited 5,005,806 0.41%
    Jadeglen Investments Pty Ltd <David Thurin Family A/C> ii 5,000,000 0.41%

    Profile

    since

    Note